Editas Medicine, Inc. 8-K

What Happened

• On May 25, 2026 (press release furnished May 26, 2026), Editas Medicine announced preclinical non‑human primate (NHP) results for its in‑vivo candidate EDIT‑401 showing rapid, dose‑dependent mean reductions of ~90% in LDL‑cholesterol (LDL‑C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) after a single dose, with durability through six months. The reductions were highly correlated and consistent with an LDL receptor upregulation mechanism. Editas reported a mean functional liver editing rate of 12.4% at the therapeutically relevant dose (1.5 mg/kg) and said EDIT‑401 was well tolerated at that dose in non‑GLP studies; higher doses (3 and 6 mg/kg) produced liver enzyme increases and adverse findings at 6 mg/kg. The company is conducting an ongoing GLP toxicology study and received pre‑IND feedback from the FDA.

Key Details

• Efficacy: Single dose produced ≥~90% mean reductions in LDL‑C, ~90% mean reductions in Lp(a), and ~90% mean reductions in ApoB in NHPs, durable through six months.
• Safety/editing: Therapeutically relevant dose = 1.5 mg/kg; mean liver editing 12.4% at 1.5 mg/kg; minimal extrahepatic editing (low in adrenal, spleen, ovary; none significant in 31 other tissues vs. control). Higher doses (3 mg/kg and 6 mg/kg) showed greater liver enzyme increases and adverse observations at 6 mg/kg.
• Clinical plans/timeline: Plans to submit a Clinical Trial Notification (CTN) in Australia mid‑2026 and aims to start a first‑in‑human Phase 1/2 trial in HeFH patients later in 2026, with topline Part 1 data expected in 2027; Part 1 ~18 patients (single ascending dose), Part 2 ~28 patients (single‑dose randomized, placebo‑controlled).
• Regulatory: Received FDA pre‑IND feedback on nonclinical package, CMC and study design, providing optionality for a U.S. IND.

Why It Matters

• For investors, these results highlight strong preclinical efficacy and an early tolerability profile at the company’s targeted therapeutic dose, supporting Editas’s plan to advance EDIT‑401 into human testing. The program targets unmet needs in heterozygous familial hypercholesterolemia (HeFH) and other ASCVD risk driven by LDL‑C and Lp(a).
• Key near‑term catalysts cited by the company are the mid‑2026 CTN submission in Australia, initiation of a first‑in‑human trial later in 2026, and early in‑vivo human proof‑of‑concept data potentially by year‑end 2026; these timelines are forward‑looking and subject to regulatory review, additional preclinical requirements, and funding. The 8‑K reiterates standard forward‑looking statement risks noted in the company’s SEC filings.